HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that its partner, BioGeneriX AG, a company of the ratiopharm Group, has been notified by the regulatory authority in a Western European jurisdiction that it is cleared to initiate a first Phase I clinical trial for Neose’s GlycoPEG-GCSF, a long-acting, GlycoPEGylated™ granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia. GlycoPEG-GCSF is being co-developed by the companies under a Research, Co-development and Commercialization Agreement entered into in April 2004 (the “GlycoPEG-GCSF Agreement”). The approved Phase I study is a single-blind, randomized, active comparator, ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GlycoPEG-GCSF in healthy volunteers.
